Not all sufferers with CLL have to have therapy. In spite of all recent advances, the iwCLL still suggests watchful observation for individuals with asymptomatic condition.86 This advice is based on at the very least two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR)